Literature DB >> 16304985

Surgical management of adrenocorticotropic hormone-secreting macroadenomas: outcome and challenges in patients with Cushing's disease or Nelson's syndrome.

Claudio De Tommasi1, Mary Lee Vance, David O Okonkwo, Alfa Diallo, Edward R Laws.   

Abstract

OBJECT: Adrenocorticotropic hormone (ACTH)-secreting pituitary macroadenomas are an uncommon cause of Cushing's disease (CD) and, subsequently, Nelson's syndrome (NS). They have been associated with low postoperative remission rates. The outcome of modern surgical treatment is unclear and thus was assessed in a series of 43 patients, with the goal of improving therapeutic results in patients with ACTH-secreting macroadenomas.
METHODS: Thirty-seven patients presented with CD and six with NS. They represented 15% of the patients surgically treated at the authors' institution for ACTH-secreting adenomas. The median patient age was 38 years (range 14-71 years), and the mean duration of follow up was 37 months (range 1-108 months). Remission occurred in 25 (67.6%) of 37 patients with CD, whereas the disease persisted in 12 (32.4%) of 37 patients. After an initial remission, three (12%) of 25 patients demonstrated signs and symptoms indicative of disease recurrence. Among patients with NS, only one (16.6%) displayed remission. Invasion of the dura mater by tumor was histologically demonstrated in 10 patients with CD and in two patients with NS.
CONCLUSIONS: Comprehensive management of CD caused by ACTH-secreting macroadenomas through the appropriate use of combination therapy, including surgery, radiotherapy, radiosurgery, and adrenalectomy, can lead to outcomes similar to those for microadenomas. Disease recurrence and persistence rates are higher, often because of the invasiveness associated with macroadenomas. Remission of NS-associated macroadenomas is difficult to achieve. Strategies for the characterization and treatment of invasive macroadenomas are needed.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16304985     DOI: 10.3171/jns.2005.103.5.0825

Source DB:  PubMed          Journal:  J Neurosurg        ISSN: 0022-3085            Impact factor:   5.115


  18 in total

1.  The dynamics of post-operative plasma ACTH values following transsphenoidal surgery for Cushing's disease.

Authors:  Lakshmi Srinivasan; Edward R Laws; Robert L Dodd; Monique M Monita; Christyn E Tannenbaum; Kjersti M Kirkeby; Olivia S Chu; Griffith R Harsh; Laurence Katznelson
Journal:  Pituitary       Date:  2011-12       Impact factor: 4.107

Review 2.  The Treatment of Cushing's Disease.

Authors:  Rosario Pivonello; Monica De Leo; Alessia Cozzolino; Annamaria Colao
Journal:  Endocr Rev       Date:  2015-06-11       Impact factor: 19.871

3.  Transsphenoidal resection of sellar tumors using high-field intraoperative magnetic resonance imaging.

Authors:  Nicholas J Szerlip; Yi-Chen Zhang; Dimitris G Placantonakis; Marc Goldman; Kara B Colevas; David G Rubin; Eric J Kobylarz; Sasan Karimi; Monica Girotra; Viviane Tabar
Journal:  Skull Base       Date:  2011-07

4.  Negative correlation between tumour size and cortisol/ACTH ratios in patients with Cushing's disease harbouring microadenomas or macroadenomas.

Authors:  M C Machado; A E E Alcantara; A C L Pereira; V A S Cescato; N R Castro Musolino; B B de Mendonça; M D Bronstein; M C B V Fragoso
Journal:  J Endocrinol Invest       Date:  2016-06-30       Impact factor: 4.256

5.  Volumetric measurement for comparison of the accuracy between intraoperative CT and postoperative MR imaging in pituitary adenoma surgery.

Authors:  C-C Lee; S-T Lee; C-N Chang; P-C Pai; Y-L Chen; T-C Hsieh; C-C Chuang
Journal:  AJNR Am J Neuroradiol       Date:  2011-06-23       Impact factor: 3.825

6.  Pituitary tumor apoplexy in patients with Cushing's disease: endocrinologic and visual outcomes after transsphenoidal surgery.

Authors:  Osamah J Choudhry; Asad J Choudhry; Elkin A Nunez; Jean Anderson Eloy; William T Couldwell; Ivan S Ciric; James K Liu
Journal:  Pituitary       Date:  2012-09       Impact factor: 4.107

7.  Transsphenoidal surgery for Cushing disease: experience with 136 patients.

Authors:  Ivan Ciric; Jin-Cheng Zhao; Hongyan Du; James W Findling; Mark E Molitch; Roy E Weiss; Samuel Refetoff; William D Kerr; Joel Meyer
Journal:  Neurosurgery       Date:  2012-01       Impact factor: 4.654

Review 8.  Management of Cushing disease.

Authors:  Nicholas A Tritos; Beverly M K Biller; Brooke Swearingen
Journal:  Nat Rev Endocrinol       Date:  2011-02-08       Impact factor: 43.330

Review 9.  Treatment of adrenocorticotropin-dependent Cushing's syndrome: a consensus statement.

Authors:  B M K Biller; A B Grossman; P M Stewart; S Melmed; X Bertagna; J Bertherat; M Buchfelder; A Colao; A R Hermus; L J Hofland; A Klibanski; A Lacroix; J R Lindsay; J Newell-Price; L K Nieman; S Petersenn; N Sonino; G K Stalla; B Swearingen; M L Vance; J A H Wass; M Boscaro
Journal:  J Clin Endocrinol Metab       Date:  2008-04-15       Impact factor: 5.958

Review 10.  An approach to the management of patients with residual Cushing's disease.

Authors:  Lewis S Blevins; Nader Sanai; Sandeep Kunwar; Jessica K Devin
Journal:  J Neurooncol       Date:  2009-04-19       Impact factor: 4.130

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.